Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978118 · ClinicalTrials.gov registry record
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
A clinical trial of Carcinoma, Renal Cell and Carcinoma, Urothelial, sponsored by Duke University.
- Active
- Registry status
- 67
- Enrollment target
- 1
- Study location
NCT02978118 is a study of Carcinoma, Renal Cell and Carcinoma, Urothelial that is active but no longer recruiting, run by Duke University. The registered enrollment target is 67 participants, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02978118, a study of Carcinoma, Renal Cell and Carcinoma, Urothelial, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study purpose of this study is to describe peripheral circulating immune cell profiles at baseline and change on treatment with immune checkpoint inhibitors in renal cell carcinoma and urothelial carcinoma.
Conditions Studied
Interventions
- DEVICE Immune cell and CTC detection procedures
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2017-03-07 |
| Est. Completion | 2028-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02978118
The ClinicalTrials.gov registry entry for NCT02978118 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (76% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Immune cell and CTC detection procedures is the first listed.
NCT02978118 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02978118 about?
NCT02978118 is a clinical study titled "Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)". This pilot study purpose of this study is to describe peripheral circulating immune cell profiles at baseline and change on treatment with immune checkpoint inhibitors in renal cell carcinoma and urothelial carcinoma.
What is the current status of trial NCT02978118?
This trial is currently active not recruiting. The enrollment target is 67 participants. The study started on 2017-03-07. Estimated completion is 2028-10.
What conditions does trial NCT02978118 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell, Carcinoma, Urothelial.
What interventions are being tested in trial NCT02978118?
The interventions under investigation include: Immune cell and CTC detection procedures (DEVICE).
Who is sponsoring clinical trial NCT02978118?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02978118 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
RECRUITING
-
Autologous Dendritic Cell Vaccine in Kidney Cancer
RECRUITING · Phase 2
-
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.